Respiratory Syncytial Virus

Codagenix scores again: $3M to hunt down deadly RSV

By GREGORY ZELLER // A fresh $3 million in public and private investments has set Codagenix Inc. on the trail of another nefarious disease. Already developing vaccines for Zika virus, the mutating menace Influenza A and a host of other viral villains, Codagenix will now focus its vaccine-creation might on Respiratory Syncytial Virus through a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health and another $1.5 million in…